Background/objectives: Cancer patients are more vulnerable to SARS-CoV-2 infection and COVID-19 due to their immunocompromised status. This study aims to evaluate the risk of SARS-CoV-2 infection, as well as COVID-19 prevalence and mortality, in cancer patients during the first wave of the COVID-19 pandemic in a virus epicenter of Northern Italy.Methods: This retrospective analysis included 40,148 prevalent cancer patients from the province of Parma, Italy, between February and June 2020. Patients were identified from health system records and classified by cancer subtype, treatment status, and COVID-19 diagnosis. The risk of infection and mortality was analyzed using odds ratios (OR) and hazard ratios (HR).Results: Among cancer patients, those on active cancer treatment had a higher cumulative risk of all-cause death (HR 1.83,p< 0.000268). Cancer subtype significantly impacted COVID-19 outcomes, with breast cancer patients showing lower incidence and mortality compared to those with lung, colorectal, or bladder cancers.Conclusions: Cancer patients, especially those on active treatment, are at increased risk of COVID-19 infection and death. Tailored prevention strategies, including prioritization of vaccination and careful management of cancer treatments, are crucial to mitigate risks during pandemics. These findings provide valuable insights for clinical decision-making in oncological care during public health crises.
背景/目的：由于免疫功能低下状态，癌症患者对SARS-CoV-2感染及COVID-19更为易感。本研究旨在评估意大利北部疫情中心地区癌症患者在COVID-19第一波大流行期间的SARS-CoV-2感染风险、COVID-19患病率及死亡率。方法：本回顾性分析纳入2020年2月至6月期间意大利帕尔马省的40,148名现患癌症患者。通过医疗系统记录识别患者，并按癌症亚型、治疗状态和COVID-19诊断进行分类。采用比值比（OR）和风险比（HR）分析感染风险和死亡率。结果：在癌症患者中，接受积极抗癌治疗的患者全因死亡累积风险更高（HR 1.83，p<0.000268）。癌症亚型显著影响COVID-19预后，与肺癌、结直肠癌或膀胱癌患者相比，乳腺癌患者的发病率和死亡率更低。结论：癌症患者，特别是接受积极治疗者，面临更高的COVID-19感染和死亡风险。在大流行期间，制定针对性预防策略（包括优先接种疫苗和谨慎管理癌症治疗）对降低风险至关重要。这些发现为公共卫生危机期间肿瘤诊疗的临床决策提供了重要参考。
肿瘤(癌症)患者之家